Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes
Tóm tắt
The high cost of fidaxomicin has restricted its use despite the benefit of a lower Clostridioides difficile infection (CDI) recurrence rate at 4 weeks of follow-up. This short follow-up represents the main limitation of pivotal clinical trials of fidaxomicin, and some recent studies question its benefits over vancomycin. Moreover, the main risk factors of recurrence after treatment with fidaxomicin remain unknown. We designed a multicentre retrospective cohort study among four Spanish hospitals to assess the efficacy of fidaxomicin in real life and to investigate risk factors of fidaxomicin failure at weeks 8 and 12. Two-hundred forty-four patients were included. Fidaxomicin was used in 96 patients (39.3%) for a first episode of CDI, in 95 patients (38.9%) for a second episode, and in 53 patients (21.7%) for a third or subsequent episode. Patients treated with fidaxomicin in a first episode were younger (59.9 years vs 73.5 years), but they had more severe episodes (52.1% vs. 32.4%). The recurrence rates for patients treated in the first episode were 6.5% and 9.7% at weeks 8 and 12, respectively. Recurrence rates increased for patients treated at second or ulterior episodes (16.3% and 26.4% at week 8, respectively). Age greater than or equal to 85 years and having had a previous episode of CDI were identified as recurrence risk factors at weeks 8 and 12. We conclude that the outcomes with fidaxomicin in real life are at least as good as those observed in clinical trials despite a more demanding evaluation. Be it 85 years of age or older, and the use after a first episode appears to be independent factors of CDI recurrence after treatment with fidaxomicin.
Tài liệu tham khảo
citation_journal_title=Clin Infect Dis; citation_title=Fidaxomicin inhibits spore production in clostridium difficile; citation_author=F Babakhani, L Bouillaut, A Gomez, P Sears, L Nguyen, AL Sonenshein; citation_volume=55; citation_publication_date=2012; citation_pages=162-169; citation_doi=10.1093/cid/cis453; citation_id=CR1
citation_journal_title=J Antimicrob Chemother; citation_title=Fidaxomicin inhibits toxin production in clostridium difficile; citation_author=F Babakhani, L Bouillaut, P Sears, C Sims, A Gomez, AL Sonenshein; citation_volume=68; citation_publication_date=2013; citation_pages=515-522; citation_doi=10.1093/jac/dks450; citation_id=CR2
citation_journal_title=Clin Infect Dis; citation_title=Fidaxomicin preserves the intestinal microbiome during and after treatment of clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI; citation_author=TJ Louie, K Cannon, B Byrne, J Emery, L Ward, M Eyben; citation_volume=55; citation_publication_date=2012; citation_pages=132-142; citation_doi=10.1093/cid/cis338; citation_id=CR3
European Medicines Agency. Dificlir. Product information. 2011.
citation_journal_title=Antimicrob Agents Chemother.; citation_title=US-Based national surveillance for fidaxomicin susceptibility of Clostridioides difficile-associated diarrheal isolates from 2013; citation_author=CM Thorpe, LA Dermott, MK Tran, J Chang, SG Jenkins, EJC Goldstein; citation_volume=63; citation_publication_date=2019; citation_pages=1-10; citation_doi=10.1128/AAC.00391-19; citation_id=CR5
citation_journal_title=N Engl J Med; citation_title=Fidaxomicin versus vancomycin for Clostridium difficile infection; citation_author=TJ Louie, MA Miller, KM Mullane, K Weiss, A Lentnek, Y Golan; citation_volume=364; citation_publication_date=2011; citation_pages=422-431; citation_doi=10.1056/NEJMoa0910812; citation_id=CR6
citation_journal_title=Lancet Infect Dis.; citation_title=Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial; citation_author=OA Cornely, DW Crook, R Esposito, A Poirier, MS Somero, K Weiss; citation_volume=12; citation_publication_date=2012; citation_pages=281-289; citation_doi=10.1016/S1473-3099(11)70374-7; citation_id=CR7
citation_journal_title=Clin Microbiol Infect.; citation_title=European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection; citation_author=SB Debast, MP Bauer, EJ Kuijper, F Allerberger, E Bouza, JE Coia; citation_volume=20; citation_publication_date=2014; citation_pages=1-26; citation_doi=10.1111/1469-0691.12418; citation_id=CR8
citation_journal_title=Clin Infect Dis; citation_title=Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA); citation_author=LC McDonald, DN Gerding, S Johnson, JS Bakken, KC Carroll, SE Coffin; citation_volume=66; citation_publication_date=2018; citation_pages=1-48; citation_doi=10.1093/cid/cix1085; citation_id=CR9
Fehér C, Múñez Rubio E, Merino Amador P, Delgado-Iribarren Garcia-Campero A, Salavert M, Merino E, et al. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort. Eur J Clin Microbiol Infect Dis [Internet]. 2017;36:295–303. Available from: http://dx.doi.org/
https://doi.org/10.1007/s10096-016-2802-x
citation_journal_title=Infection; citation_title=Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital; citation_author=M Pichenot, R Héquette-Ruz, R Guern, B Grandbastien, C Charlet, F Wallet; citation_volume=45; citation_publication_date=2017; citation_pages=425-431; citation_doi=10.1007/s15010-017-0981-8; citation_id=CR11
citation_journal_title=J Hosp Infect.; citation_title=Real-world use of fidaxomicin in a large UK tertiary hospital: how effective is it for treating recurrent disease?; citation_author=DA Enoch, R Santos, CJ Phillips, C Micallef, ME Murphy, SH Aliyu; citation_volume=100; citation_publication_date=2018; citation_pages=142-146; citation_doi=10.1016/j.jhin.2018.05.001; citation_id=CR12
citation_journal_title=J Clin Gastroenterol; citation_title=Outcomes with fidaxomicin therapy in clostridium difficile infection; citation_author=CM Spiceland, S Khanna, DS Pardi; citation_volume=52; citation_publication_date=2018; citation_pages=151-154; citation_doi=10.1097/MCG.0000000000000769; citation_id=CR13
citation_journal_title=Eur J Clin Microbiol Infect Dis; citation_title=Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE); citation_author=MJGT Vehreschild, S Taori, SD Goldenberg, F Thalhammer, E Bouza, J Oene; citation_volume=37; citation_publication_date=2018; citation_pages=2097-2106; citation_doi=10.1007/s10096-018-3344-1; citation_id=CR14
citation_journal_title=Clin Microbiol Infect.; citation_title=Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study; citation_author=CA Gentry, PK Nguyen, S Thind, G Kurdgelashvili, GH Skrepnek, RJ Williams; citation_volume=25; citation_issue=8; citation_publication_date=2019; citation_pages=987-993; citation_doi=10.1016/j.cmi.2018.12.007; citation_id=CR15
citation_journal_title=J Clin Pharm Ther; citation_title=Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection; citation_author=JD Tieu, RJ Williams, GH Skrepnek, CA Gentry; citation_volume=44; citation_publication_date=2019; citation_pages=220-228; citation_doi=10.1111/jcpt.12771; citation_id=CR16
citation_journal_title=Lancet Infect Dis.; citation_title=Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial; citation_author=B Guery, F Menichetti, VJ Anttila, N Adomakoh, JM Aguado, K Bisnauthsing; citation_volume=18; citation_publication_date=2017; citation_pages=296-307; citation_doi=10.1016/S1473-3099(17)30751-X; citation_id=CR17
citation_journal_title=Clin Infect Dis.; citation_title=A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity; citation_author=FA Zar, SR Bakkanagari, KM Moorthi, MB Davis; citation_volume=45; citation_publication_date=2007; citation_pages=302-307; citation_doi=10.1086/519265; citation_id=CR18
citation_journal_title=J Clin Microbiol; citation_title=Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile; citation_author=P Bidet, V Lalande, B Salauze, B Burghoffer, V Avesani, M Delmée; citation_volume=38; citation_publication_date=2000; citation_pages=2484-2487; citation_doi=10.1128/JCM.38.7.2484-2487.2000; citation_id=CR19
citation_journal_title=PLoS ONE; citation_title=Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile; citation_author=WN Fawley, CW Knetsch, DR MacCannell, C Harmanus, T Du, MR Mulvey; citation_volume=10; citation_publication_date=2015; citation_pages=1-14; citation_id=CR20
citation_journal_title=Int J Antimicrob Agents.; citation_title=Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score; citation_author=J Cobo, E Merino, C Martínez, A Cózar-llistó, E Shaw, T Marrodán; citation_volume=51; citation_publication_date=2018; citation_pages=393-398; citation_doi=10.1016/j.ijantimicag.2017.09.010; citation_id=CR21
citation_journal_title=J Am Geriatr Soc; citation_title=Effect of age on treatment outcomes in Clostridium difficile infection; citation_author=TJ Louie, MA Miller, DW Crook, A Lentnek, L Bernard, KP High; citation_volume=61; citation_publication_date=2013; citation_pages=222-230; citation_doi=10.1111/jgs.12090; citation_id=CR22
citation_journal_title=Clin Infect Dis; citation_title=Bezlotoxumab for prevention of recurrent clostridium difficile infection in patients at increased risk for recurrence; citation_author=DN Gerding, CP Kelly, G Rahav, L Christine, ER Dubberke, PN Kumar; citation_volume=67; citation_publication_date=2018; citation_pages=649-656; citation_doi=10.1093/cid/ciy171; citation_id=CR23